Searchable abstracts of presentations at key conferences in endocrinology

ea0086p106 | Neuroendocrinology and Pituitary | SFEBES2022

Identifying and characterising variants in patients with pachydermoperiostosis

Angurala Ishita , Barry Sayka , Rice Tom , Magid Kesson , Rai Ashutosh , Benjamin Loughrey Paul , Dutta Pinaki , Stelmachowska Banaś Maria , Korbonits Marta

Introduction: Pachydermoperiostosis (primary hypertrophic osteoarthropathy, PHOA) is a rare genetic condition characterised by digital clubbing, pachydermia, hyperhidrosis, cutis verticis gyrata and periostosis. The SLCO2A1 transporter and HPGD enzyme genes play an important role in prostaglandin metabolism, hence loss of function mutations in them causes PHOA. To date, according to the VarSome database 101 and 41 variants have been identified in the SLCO...

ea0077p212 | Neuroendocrinology and Pituitary | SFEBES2021

Cabergoline treatment in human primary non-functioning pituitary adenomas

Begalli Federica , Komagata Tatsuya , Suleyman Oniz , Magid Kesson , Rice Thomas , Collier David , Dorward Neil , Grieve Joan , Mendoza Nigel , Nair Ramesh , Kolias Angelos , Khan Danyal , Marcus Hani J , Botta Joaquin , McCormick Peter J , Shinozaki Koji , Korbonits Marta

Non-functioning pituitary adenomas (NFPAs) are the second most common subtype (15-43%) of all clinically presenting pituitary adenomas. Although the primary treatment of symptomatic NFPAs is surgery, gross total resection is achieved only in about 66% of the cases, and 20% of gross total resected tumours recur after 10 years. Despite recent advances in medical management of pituitary tumours, NFPAs remain the only subtype with no widely accepted pharmacological treatment. Expr...

ea0094oc3.1 | Neuroendocrinology and Pituitary | SFEBES2023

CDC42: a potential therapeutic target of clinically non-functioning pituitary neuroendocrine tumours

Rai Ashutosh , Begalli Federica , Barry Sayka , Rice Thomas , Magid Kesson , Suleyman Oniz , Dorward Neil , Grieve Joan , Kolias Angelos , Khan Danyal , J Marcus Hani J. , Radotra Bishan D. , Chhabra Rajesh , Dhandapani S S. , Tripathi Manjul , Ahuja Chirag K. , Dutta Pinaki , Korbonits Marta

Background: There is no effective medical treatment available for non-functioning pituitary neuroendocrine tumours (NF-PitNETs). Recurrence (7-12%) or incomplete resection (30-45%) is a common feature. Thus, finding novel medical therapies to help the management of these tumours would be of great value. By using high-throughput mass spectrometry combined with functional characterisation, we explored novel therapeutic targets for NF-PitNETs.<p class="abstex...